Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares some insights into the promise of bispecific antibodies, such as elranatamab, for the treatment of triple-class refractory myeloma patients. Dr Ramasamy highlights the promise that these agents have shown in clinical trials, and the importance of further investigating and better understanding how to manage the side effects of bispecific antibodies. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.